Enanta Pharmaceuticals, Inc. v. Pfizer Inc. (Fed. Cir., June 23, 2026) 2025-1427
In this episode, the United States Court of Appeals for the Federal Circuit affirmed a lower court's ruling that Enanta Pharmaceuticals' patent regarding coronavirus treatments is invalid. The central dispute involved whether a typographical error in a provisional application—listing a chemical range starting with two carbon atoms instead of one—could be corrected to secure an earlier priority date. Because the original filing failed to explicitly describe the specific one-carbon compound used in Pfizer’s Paxlovid, the court determined that Enanta did not technically possess the invention at…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.